Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors

Journal of Endocrinology

Volumn 157, Issue 2, 1998, Pages 337-341

  Takeuchi, S ^a,c   Koeffler, H P ^a   Hinton, D R ^b   Miyoshi, I ^c   Melmed, S ^a   Shimon, I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; GENE DELETION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE STRAND CONFORMATION POLYMORPHISM;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DNA MUTATIONAL ANALYSIS; ENZYME INHIBITORS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOENZYME TECHNIQUES; MICROTUBULE-ASSOCIATED PROTEINS; PITUITARY NEOPLASMS; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0031809905     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1570337     Document Type: Article

References (42)

1. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI & Slingerland JM 1997 Decreased levels of the cell-cycle inhibitor p27Kipl protein: prognostic implications in primary breast cancer. Nature Medicine 3 227-230.
2. EI-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW & Vogelstein B 1993 WAF1. a potential mediator of p53 tumor suppression. Cell 75 817-825.
3. Faccenda E, Melmed S, Bevan JS & Eidne KA 1996 Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas. Clinical Endocrinology 44 341-347.
4. Kip1-deficient mice. Cell 85 733-744.
5. Gu Y, Turck CW & Morgan DO 1993 Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366 707-710.
6. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes and Development 8 2939-2952.
7. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371 257-261.
8. Harper JW, Adami GR, Wei N, Keyomarsi K & Elledge SJ 1993 The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 805-816.
9. Herman V, Drazin NZ, Gonsky R & Melmed S 1993 Molecular screening of pituitary adenomas for gene mutations and rearrangements. Journal of Clinical Endocrinology and Metabolism 77 50-55.
10. Hirama T & Koeffler HP 1995 Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86 841-854.
11. Hunter T 1993 Braking the cycle. Cell 75 839-841.
12. Kamb A, Gruis NA, Weaver-Feldhaus J, Lin Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE & Skolnick MH 1994 A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 436-440.
13. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Lee YY, Bartram CR & Koeffler HP 1995 Molecular analysis of the cyclin-dependent kinase inhibitor p27/kip1 gene in human malignancies. Cancer Research 55 2266-2269.
14. Kip1. Cell 85 721-732.
15. Levy A, Hall L, Yeudall WA & Lightman SL 1994 p53 gene mutations in pituitary adenomas: rare events. Clinical Endocrinology 41 809-814.
16. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM & Pagano M 1997 Increased proteasome-dependent degration of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 3 231-234.
17. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes and Development 9 650-662.
18. KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 86 1924-1930.
19. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 707-720.
20. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K & Carson AD 1994 Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 753-756.
21. Pei L, Melmed S, Scheithauer B, Kovacs K & Prager D 1994 H-ras mutations in human pituitary carcinoma metastases. Journal of Clinical Endocrinology and Metabolism 78 842-846.
22. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF & Prager D 1995 Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Research 55 1613-1616.
23. kip1 gene to 12p13 and its analysis in leukemia. Cancer Research 55 1206-1210.
24. Pines J 1993 Cyclins and cyclin-dependent kinases; take your partners. Trends in Biochemical Sciences 18 195-197.
25. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 59-66.
26. Kip1: chromosomal mapping to 12p12-12p131 and absence of mutations in human tumors. Cancer Research 55 1211-1214.
27. Porter P, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR & Roberts JM 1997 Expression of cell-cycle regulation of p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 3 222-225.
28. Reed SI 1992 The role of p34 kinases in the G1 to S-phase transition. Annual Review of Cell Biology 8 529-561.
29. Kip1 gene in childhood acute lymphoblastic leukemia (ALL). Leukemia 10 345.
30. Serrano M, Hannon GJ & Beach D 1993 A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK 4. Nature 366 704-707.
31. Sherr CJ 1993 Mammalian G1 cyclins. Cell 73 1059-1065.
32. Shi S-R, Imam A, Young L, Cote R & Taylor CR 1995 Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies. Journal of Histochemistry and Cytochemistry 43 193-201.
33. Shimon I & Melmed S 1997 Genetic basis of endocrine disease: pituitary tumor pathogenesis. Journal of Clinical Endocrinology and Metabolism 82 1675-1681.
34. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B & Koeffler HP 1994 Absence of WAF1 mutations in a variety of human malignancies. Blood 84 3781-3784.
35. Spinn KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW & Koeffler HP 1996 p27/Kip1 mutation found in breast cancer. Cancer Research 56 2400-2404.
36. Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP & Gilliland DG 1996 Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Research 56 1413-1417.
37. Takeuchi S, Bartram CR, Serin T, Miller CW, Tobler A, Janssen JWG, Reiter A, Ludwig W-D, Zimmermann M, Schwaller J, Lee E, Miyoshi I & Koeffler HP 1995 Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A and p18 genes in acute lymphoblastic leukemia of childhood. Blood 86 755-760.
38. Takeuchi S, Mori N, Koike M, Slater J, Park S, Miller CW, Miyoshi I & Koeffler HP 1996 Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Research 56 738-740.
39. Takino H, Herman V, Weiss M & Melmed S 1995 Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. Journal of Clinical Endocrinology and Metabolism 80 1733-1738.
40. Toyoshima H & Hunter T 1994 p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78 67-74.
41. INK4a product in human pituitary tumors. Cancer Research 56 2493-2496.
42. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R & Beach D 1993 p21 is a universal inhibitor of cyclin kinases. Nature 366 701-703.